TARS Stock Overview
A commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tarsus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.88 |
| 52 Week High | US$42.50 |
| 52 Week Low | US$12.57 |
| Beta | 1.06 |
| 11 Month Change | -13.42% |
| 3 Month Change | -20.82% |
| 1 Year Change | 58.32% |
| 33 Year Change | -4.59% |
| 5 Year Change | n/a |
| Change since IPO | 35.47% |
Recent News & Updates
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26
Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Recent updates
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
Sep 07Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
May 13Shareholder Returns
| TARS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.6% | 1.8% |
| 1Y | 58.3% | 22.2% | 24.2% |
Return vs Industry: TARS exceeded the US Pharmaceuticals industry which returned 21.8% over the past year.
Return vs Market: TARS exceeded the US Market which returned 24% over the past year.
Price Volatility
| TARS volatility | |
|---|---|
| TARS Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TARS's share price has been volatile over the past 3 months.
Volatility Over Time: TARS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 244 | Bobby Azamian | www.tarsusrx.com |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. Fundamentals Summary
| TARS fundamental statistics | |
|---|---|
| Market cap | US$1.05b |
| Earnings (TTM) | -US$148.20m |
| Revenue (TTM) | US$42.56m |
24.7x
P/S Ratio-7.1x
P/E RatioIs TARS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARS income statement (TTM) | |
|---|---|
| Revenue | US$42.56m |
| Cost of Revenue | US$53.56m |
| Gross Profit | -US$11.00m |
| Other Expenses | US$137.21m |
| Earnings | -US$148.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.92 |
| Gross Margin | -25.84% |
| Net Profit Margin | -348.22% |
| Debt/Equity Ratio | 10.9% |
How did TARS perform over the long term?
See historical performance and comparison